← Back to Clinical Trials
Recruiting NCT07518056

NCT07518056 Relationships Between Nomophobia Levels and Perceived Stress, Body Image and Food Addiction Among University Students

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07518056
Status Recruiting
Phase
Sponsor Bahçeşehir University
Condition Nomofobia
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2026-02-10
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 30 Years
Study Type OBSERVATIONAL
Interventions
Questionnaires on Nomophobia, Perceived Stress, Body Image, and Food Addiction; Body Composition and Anthropometric Measurements via Bioelectrical Impedance Analysis

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2026-02-10 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to examine the effects of nomophobia levels on stress, food addiction, and body image among undergraduate students aged 18-30 at Bahçeşehir University, Faculty of Health Sciences. The primary questions it aims to answer are: * Is there a statistically significant relationship between nomophobia levels and perceived stress, food addiction, and body image among university students? * Is there a correlation between objective anthropometric data (body fat percentage, skeletal muscle mass) measured via Bioelectrical Impedance Analysis (BIA), waist/hip circumference measurements, and the individual's perceived body image?

Eligibility Criteria

Inclusion Criteria: * Being an active smartphone user * Reading and providing consent via the Informed Consent Form * Absence of conditions such as pacemaker implantation, metallic prostheses in the body, or pregnancy * Not having a diagnosed metabolic disorder (e.g., Cushing's syndrome, diabetes, thyroid disorders) or any acute/chronic psychiatric condition that may affect eating behavior Exclusion Criteria: * Individuals with a current diagnosis of an eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder, etc.) * Individuals with a psychiatric diagnosis of severe depression, bipolar disorder, psychotic disorder, or an anxiety disorder requiring treatment * Individuals who regularly use psychiatric medications (e.g., SSRIs, SNRIs, antipsychotics, mood stabilizers, etc.) * Individuals who have used corticosteroids or similar hormone-regulating medications in the past 3 months * Pregnant or breastfeeding individuals * Participants who did not complete the questionnaires or the measurement procedures

Contact & Investigator

Central Contact

Beyza Terzioğlu

✉ beyzaterziogluu@gmail.com

📞 +90 212 381 91 52

Principal Investigator

Beyza Terzioğlu

PRINCIPAL INVESTIGATOR

Bahçeşehir University

Frequently Asked Questions

Who can join the NCT07518056 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 30 Years, studying Nomofobia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07518056 currently recruiting?

Yes, NCT07518056 is actively recruiting participants. Contact the research team at beyzaterziogluu@gmail.com for enrollment information.

Where is the NCT07518056 trial being conducted?

This trial is being conducted at Istanbul, Turkey (Türkiye).

Who is sponsoring the NCT07518056 clinical trial?

NCT07518056 is sponsored by Bahçeşehir University. The principal investigator is Beyza Terzioğlu at Bahçeşehir University. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology